Plus: Millennials don't invest like the rest of us, mid-cap stocks to the rescue, and Big Pharma pulls a fast one
Investors and money managers caught off guard by commodity markets.
The $3.2 billion fund, launched in 1969, will be merged into smaller large-cap growth fund.
Sometimes an ETF isn't exactly an ETF
Much of the movement away has been led by advisers looking for cheaper and easier ways to build client portfolios.
EGA is a provider of emerging markets smart-beta funds.
Those as well as energy-producing states are seeing worsening balance sheets.
Regulator is looking into whether firms have a process and supervisory procedures in place to waive fees.
Customizing portfolios introduces human frailty and failure.
The investment strategy has only outperformed buy and hold 24% of the time since the end of 1990, according to S&P Global.
As with equities, passive funds are often the better bet.
The tech giant's shares have tumbled more than15% since mid-April, dragging down funds with heavy exposure to the stock.
Some muni funds, such as Oppenheimer, are over-exposed to the risky bonds.
Offerings from iCapital, CAIS and Goldman Sachs now available.
Closet indexers virtually guarantee lagging performance
Beleaguered fund fights to find footing after ill-fated Valeant Pharma bet.
A $2 billion payment is due July 1 and funds still have big chunks of the bonds in their portfolios.
The move is another sign that the days of high-cost funds are numbered, and that the Department of Labor's new rule is speeding that decline.
The simplest strategy often turns out to be the best.
